Polaris Group

Tdw Group

Bor-Wen Wu

John S Bomalaski

James A Thomson

Wei He

Yunyun Guo

Robert Almassy

Richard E Showalter

Jiaojuan He

Wen-Chin Tsai

Provided are lyophilized formulations comprising pegylated arginine deiminase (ADI-PEG) and related reconstituted liquid compositions and methods of using the compositions for arginine depletion therapies, including for the treatment of various cancers.

Formulations of pegylated arginine deiminase

The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.

Methods of treatment with arginine deiminase

Provided are chimeric arginine deiminases, including pegylated chimeric arginine deiminases, and related compositions and methods of use thereof, including methods of treating cancer.

Engineered chimeric pegylated ADI and methods of use

Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.

Growing community of inventors

San Diego, CA, United States of America

Bor-Wen Wu